Casdatifan showed a 35% confirmed ORR in the 100 mg cohort, with median PFS not reached, indicating promising efficacy. The pooled analysis revealed a 31% ORR and a median PFS of 12.2 months, ...

EG110A targets type C sensory neurons to manage neurogenic detrusor overactivity-related incontinence, preserving other bladder controls. Fast track designation by the FDA allows EG110A to benefit ...

Findings showed that although most applicants emphasized work ethic and interpersonal skills, these attributes were not predictive of receiving an interview invitation. In this video, Sevann Helo, MD, ...

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

A. Lenore Ackerman, MD, PhD, outlines the rationale for a guideline recommendation suggesting that D-mannose alone may not be effective for UTI prophylaxis. Ackerman is a urogynecologist at the ...

FDA approved gemcitabine intravesical system for BCG-unresponsive NMIBC, showing an 82% complete response rate in the SunRISe-1 trial. CAN-2409 plus valacyclovir significantly improved disease-free ...

The FloStent device showed promise in enabling catheter-free voiding in BPH-related urinary retention, with improved symptom scores and quality of life. HoLEP is gaining popularity for its ...

The Expert APProach: Conversations in Uro-Oncology, hosted by Joy Maulik, CRNP, is the latest multimedia program from Urology Times. In this debut episode of The Expert APProach: Conversations in ...

Flibanserin received FDA priority review for expanded use in postmenopausal women with hypoactive sexual desire disorder, building on its 2015 approval for premenopausal women. Gepotidacin was ...

Zenflow's Spring Scope, a single-use cystoscope, received FDA 510(k) clearance, featuring a 12 French working channel for improved visualization. The Zenflow Spring System showed a 46% improvement in ...

FDA approvals of Pluvicto and darolutamide offer new treatment options for metastatic prostate cancer, improving progression-free survival and quality of life. Genomic testing and advanced imaging ...

Adjuvant radiotherapy post-cystectomy significantly improves locoregional failure-free survival and disease-free survival in muscle-invasive bladder cancer without increasing severe late toxicity. The ...